Study Details
A Study of ASP1570 taken by itself or with pembrolizumab in adults with advanced solid tumors
Clinicaltrials.gov ID
Astellas Study ID
1570-CL-0101
EudraCT ID
N/A
Condition
Advanced/Metastatic Cancer
Phase
Phase 1
Age
18 Years - N/A
Sex
Female & Male
Product
ASP1570
Type
Interventional
Trial Dates
Oct 2021 - Apr 2027
Masking
None (Open Label)
Enrollment number
266
A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumors
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP1570 taken by itself or with pembrolizumab in adults with advanced solid tumors? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Nebraska Methodist Hospital
Omaha, United States, 68130
Mary Crowley Research Center
Dallas, United States, 75230
Providence Medical Foundation
Fullerton, United States, 92835
Tennessee Oncology
Nashville, United States, 37203
Florida Cancer Specialist & Research Institute Sarasota
Sarasota, United States, 34232
University Hospitals Cleveland Medical Center
Cleveland, United States, 44106
UPMC Hillman Cancer Center
Pittsburgh, United States, 15232
University of Chicago
Chicago, United States, 60637
University of Kentucky Medical Center MCC-CRO
Lexington, United States, 40536
USC/Norris Comprehensive Cancer Center
Los Angeles, United States, 90033
University of Kentucky Medical Center MCC-CRO
Nashville, United States, 37203
Cancer Institute Hospital Of JFCR
Koto-ku, Japan
National Cancer Center Hospital
Chuo-ku, Japan